• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, May 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Joseph Moskal elected to medical and biological engineering elite

Bioengineer by Bioengineer
February 14, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Sally Ryan

Northwestern University's Joseph R. Moskal has been elected to the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows. Moskal was cited for his studies of the NMDA receptor, which have led to the design and development of novel therapeutics for the treatment of depression.

Moskal, a distinguished research professor in Northwestern's Department of Biomedical Engineering, is among 145 engineers who make up the College of Fellows Class of 2017. They will be inducted during AIMBE's 2017 annual meeting on March 20 in Washington, D.C.

The College of Fellows comprises the top two percent of medical and biological engineers in the country. Current AIMBE Fellows have received some of the nation's highest awards, including the Presidential Medal of Science and Presidential Medal of Technology and Innovation. Many are also members of the National Academy of Engineering, National Academy of Medicine, and National Academy of Sciences.

"I am honored to join such an elite group of engineers," said Moskal, founding director of Northwestern's Falk Center for Molecular Therapeutics. "I hope this will help motivate the next generation to continue to develop what we have only begun to understand."

Moskal founded and served as chief scientific officer of Naurex, Inc., a drug discovery company that develops therapies for difficult-to-treat depression and other central nervous system diseases. While at Naurex, his team developed rapastinel, a novel therapy for treatment-resistant major depression, which is now in phase III clinical trials. In 2015, Allergan acquired Naurex for $1.7 billion.

Now, Moskal is the co-founder of Aptinyx, Inc., which targets areas of pain, post-traumatic stress disorder, and traumatic brain injury for therapeutic development. Last year, he was inducted into the National Academy of Inventors and the Chicago Area Entrepreneurship Hall of Fame.

###

Media Contact

Megan Fellman
[email protected]
847-491-3115
@northwesternu

http://www.northwestern.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Hepatic SNHG9 Connects Gut Microbiota to Liver Defense

May 20, 2026

NCCN Reinforces Global Commitment to Cancer-Related Distress Resources in Observance of Mental Health Awareness Month

May 20, 2026

Introducing AGA’s New President: Dr. Byron L. Cryer

May 20, 2026

Targeted Therapy Enhances Mobility in Children with Rare Bone Disorder

May 20, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    New Study Reveals Plants Can Detect the Sound of Rain

    732 shares
    Share 292 Tweet 183
  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    846 shares
    Share 338 Tweet 212
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    281 shares
    Share 112 Tweet 70
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Hepatic SNHG9 Connects Gut Microbiota to Liver Defense

NCCN Reinforces Global Commitment to Cancer-Related Distress Resources in Observance of Mental Health Awareness Month

Introducing AGA’s New President: Dr. Byron L. Cryer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.